The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS ...
Clinical trial results are expected by end of 2026 to guide dose selection for future ALS/MND and Parkinson’s studies. Credit ...
QRL-101, an oral small molecule being developed by QurAlis, was safe and reduced nerve-cell overactivity in ALS patients in ...
An update from Pharmaust Limited ( ($AU:NUZ) ) is now available. Neurizon Therapeutics has provided a regulatory update on NUZ-001, its ...
The trial enrolled 12 ALS patients and assessed three dose levels. Credit: Green Apple/Shutterstock.com. QurAlis has announced topline results from its Phase I proof-of-mechanism clinical trial of QRL ...
NEALS, the world's largest ALS research consortium, has selected the COYA 302 trial and it is now affiliated with NEALS as part of its mission to accelerate the development of new treatments for ...
LA JOLLA, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange ...
This funding was awarded through the ALS Association's Hoffman ALS Clinical Trial Awards Program, which aims to accelerate the development of new ALS treatments ARLINGTON, Va., Dec. 4, 2025 ...
CLEVELAND—Amyotrophic lateral sclerosis (ALS), known as Lou Gehrig’s disease, is an incurable neurological disorder affecting motor neurons—nerve cells in the brain and spinal cord that control ...
Clinical Trials Arena on MSN
QurAlis announces Phase I QRL-101 trial topline results in ALS
Kv7.2/7.3 channels are voltage-gated potassium channels involved in regulating membrane potential and neuronal excitability.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback